pyrroles has been researched along with candesartan in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armando, I; Bregonzio, C; Juorio, A; Macova, M; Pavel, J; Saavedra, JM; Sanchez-Lemus, E | 1 |
| Hirase, T; Inoue, T; Node, K; Wang, D | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, JA | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, J | 1 |
| Gaur, V; Kumar, A | 1 |
| Fujii, N; Inoue, H; Kameyama, T; Matsuki, A; Nozawa, T; Ohori, T; Shida, T; Sobajima, M; Suzuki, T | 1 |
| Fagan, SC; Guan, W; Kozak, A | 1 |
| Dohnal, J; Grunwaldova, V; Jampilek, J; Kral, V; Vaculikova, E | 1 |
8 other study(ies) available for pyrroles and candesartan
| Article | Year |
|---|---|
A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding.
Topics: Amphibian Proteins; Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autoradiography; Behavior, Animal; Benzimidazoles; Benzodiazepines; Biphenyl Compounds; Cerebral Cortex; Disease Models, Animal; Flunitrazepam; GABA Modulators; In Situ Hybridization; Male; Maze Learning; Peptide Hormones; Peptides; Protein Binding; Pyrimidines; Pyrroles; Rats; Receptor, Angiotensin, Type 2; Receptors, Corticotropin-Releasing Hormone; RNA, Messenger; Social Isolation; Stress, Physiological; Tetrazoles; Tyrosine 3-Monooxygenase | 2006 |
Atorvastatin inhibits angiotensin II-induced T-type Ca2+ channel expression in endothelial cells.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Calcium Channels, T-Type; Cells, Cultured; Endothelial Cells; Flavonoids; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Microscopy, Fluorescence; Pyrroles; ras Proteins; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tetrazoles; Vasoconstrictor Agents | 2006 |
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Family Practice; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Middle Aged; Patient Satisfaction; Pyrroles; Simvastatin; Tetrazoles; Treatment Outcome | 2007 |
Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cholesterol; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Losartan; Male; Pyrroles; Retrospective Studies; Simvastatin; Tetrazoles; Therapeutic Equivalency; Treatment Outcome | 2008 |
Neuroprotective potentials of candesartan, atorvastatin and their combination against stroke induced motor dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Behavior, Animal; Benzimidazoles; Biphenyl Compounds; Brain; Brain Ischemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitochondria; Motor Activity; Movement Disorders; Neurons; Organ Specificity; Oxidative Stress; Pyrroles; Random Allocation; Rats; Rats, Wistar; Reperfusion Injury; Stroke; Tetrazoles | 2011 |
Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Benzimidazoles; Biomarkers; Biphenyl Compounds; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Dinoprost; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Longitudinal Studies; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Tetrazoles; Tomography, X-Ray Computed | 2011 |
Drug repurposing for vascular protection after acute ischemic stroke.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Brain Infarction; Diabetes Mellitus, Type 2; Disease Models, Animal; Enalapril; Enzyme-Linked Immunosorbent Assay; Functional Laterality; Hemoglobins; Hemorrhage; Heptanoic Acids; Male; Matrix Metalloproteinase 9; Pyrroles; Rats; Rats, Inbred SHR; Rats, Wistar; Reperfusion; Stroke; Tetrazoles; Vascular System Injuries | 2011 |
Preparation of candesartan and atorvastatin nanoparticles by solvent evaporation.
Topics: Acetone; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Carboxymethylcellulose Sodium; Desiccation; Dextrans; Excipients; Heptanoic Acids; Methylene Chloride; Nanospheres; Particle Size; Polyethylene Glycols; Polysorbates; Pyrroles; Sodium Dodecyl Sulfate; Solubility; Solvents; Surface-Active Agents; Tetrazoles | 2012 |